Efficacy and Safety of Modified FOLFOXIRI+ α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.

Conclusion Based on the RR, Conv R, and symptom palliation ability, mFOLFOXIRI+α was suggested to be a viable candidate for first-line treatment for patients with ARCC, especially those with a high tumor burden. PMID: 32074573 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32074573?dopt=Abstract

Source: Internal Medicine - February 20, 2020 Category: Internal Medicine Tags: Intern Med Source Type: research